Clinical trials: Idarubicin
Leukemia
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of…
- Trial name
- NCT00469859
- Testing
- cytarabine, idarubicin, lestaurtinib
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma (HCC)
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Dear Sir/Madam, We would like to invite you to participate in this clinical research, which has been approved by the Medical Ethics Committee of Zhejiang Cancer Hospital.
- Trial name
- HAICI (NCT06741020)
- Testing
- Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Acute Myeloid Leukemia
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old
The study will include newly-diagnosed AML patients, not suffering acute promyelocytic leukemia; aged 18-60 years, who are eligible for standard induction chemotherapy.
- Trial name
- PALG-AML1/2016 (NCT03257241)
- Testing
- A arm (DA-90), B arm (DAC), A arm (CLAG-M)
- Where
- 10 sites in United States, Poland
- Volunteers
- 582 people
- Sponsor
- Polish Adult Leukemia Group
Leukemia, Leukemia, Acute
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this…
- Conditions
- Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell
- Trial name
- NCT03564470
- Testing
- Chidamide, Dasatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia
Phase III Trial in Acute Promyelocytic Leukemia Patients
Open label, randomised, phase III multicenter trial.
- Trial name
- APL0406 (NCT00482833)
- Testing
- arsenic trioxide, idarubicin, mercaptopurine
- Where
- 110 sites in Austria, Germany and 1 more
- Volunteers
- 276 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
MDS
Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes
In order to improve the overall survival benefit observed with AZA in higher risk MDS, its combination with other active drugs in MDS must be tested.
- Trial name
- AZA-PLUS (NCT01342692)
- Testing
- Azacitidine, Azacitidine associated with Valproic acid, Azacitidine associated with Lenalidomide
- Where
- France
- Volunteers
- 320 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia, Promyelocytic, Acute
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis.
- Trial name
- NCT00180128
- Testing
- all-trans retinoid acid, idarubicin, mitoxantrone
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia
3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
The goal: to evaluate the role of high dose ara-c plus idarubicin and mitoxantrone consolidation followed by maintenance in the setting of high total cumulative anthracyclines dose(720-660 mg/m2).
- Trial name
- NCT01587430
- Testing
- high dose ARA-C, standard dose ARA-C
- Where
- Russia
- Volunteers
- 245 people
- Sponsor
- National Research Center for Hematology, Russia
Leukemia
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy to kill…
- Trial name
- NCT00002701
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- 71 sites in Austria, Belgium and 7 more
- Volunteers
- 750 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04375631
- Testing
- Cladribine, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia (AML)
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
This study aims to evaluate the efficacy and safety of venetoclax combined with azacitidine and mitoxantrone hydrochloride liposome (MVA) versus idarubicin combined with cytarabine (IA) in the treatment of newly diagnosed AML.
- Trial name
- NCT07486479
- Testing
- Mitoxantrone Hydrochloride Liposome, Venetoclax, Azacitidine
- Where
- 21 sites in China
- Volunteers
- 204 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, FLT3 Gene Mutation
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the efficacy of gilteritinib as induction therapy in FLT3-positive adult acute myeloid leukemia patients.
- Conditions
- Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML, Diagnosis
- Trial name
- NCT06667973
- Testing
- Gilteritinib
- Volunteers
- 80 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Relapse/Recurrence
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia.
- Trial name
- IMPACT-AML (NCT06713837)
- Testing
- High intensity therapies, Low intensity therapies
- Where
- 51 sites in Czechia, Germany and 6 more
- Volunteers
- 339 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acute Myeloid Leukemia
Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML
Characterizing the regimen limiting toxicity (RLT) of chemotherapeutic drug Calaspargase Pegol-mknl as remission induction and consolidation chemotherapy in patients with newly diagnosed Acute Myeloid Leukemia (AML) and…
- Trial name
- NCT04953780
- Testing
- Calaspargase pegol-mknl
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
Association group of therapeutic specialities authorized in a remission induction treatment(FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin) and an intensive postremission treatment with authorized…
- Trial name
- FLAG-IDA (NCT00487448)
- Testing
- Fludarabine, Cytarabine, G-CSF
- Where
- 15 sites in Spain
- Volunteers
- 200 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute…
- Trial name
- NCT01802333
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride
- Where
- 447 sites in United States, Canada
- Volunteers
- 754 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Neutropenia
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002658
- Testing
- filgrastim, amsacrine, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00096148
- Testing
- idarubicin, cytarabine, bevacizumab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC.
- Trial name
- NCT02920008
- Testing
- guadecitabine, Treatment Choice (TC)
- Where
- 95 sites in United States, Belgium and 13 more
- Volunteers
- 302 people
- Sponsor
- Astex Pharmaceuticals, Inc.
T-lymphoblastic Lymphoma, Relapsed Disease
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for relapsed and refractory T lymphoblastic lymphoma/leukemia.
- Conditions
- T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia
- Trial name
- NCT05576532
- Testing
- BCL2 Inhibitor plus IM2 regimen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine